Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas
2003

Serious Adverse Events After Mectizan Treatment for Onchocerciasis

Sample size: 207 Editorial Evidence: moderate

Author Information

Author(s): Brian Duke, Michael J Brown

Primary Institution: River Blindness Foundation

Hypothesis

What are the risks and management strategies for serious adverse events following Mectizan treatment in areas co-endemic for Loa loa?

Conclusion

The report emphasizes the need for careful management and education regarding the risks of Loa-encephalopathy following Mectizan treatment.

Supporting Evidence

  • 65 cases of Loa-encephalopathy were temporally related to Mectizan treatment.
  • 85% of the cases were in males.
  • 93% of cases followed the first dose of ivermectin.
  • 97% of cases were reported from Cameroon.
  • The mean time to onset of symptoms was 1.7 days.

Takeaway

This study looks at the risks of a serious brain condition that can happen after taking a medicine for river blindness, especially in certain areas.

Methodology

The report reviews data from past reports and discusses the risks associated with Mectizan treatment in co-endemic areas.

Potential Biases

Potential bias in reporting cases due to differences in healthcare access in various regions.

Limitations

The exact pathogenesis of Loa-encephalopathy is not fully understood, and the report relies on historical data.

Participant Demographics

Among the 207 cases, 85% were male, and the mean age was 39.9 years.

Digital Object Identifier (DOI)

10.1186/1475-2883-2-S1-S1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication